RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Another Reorganization for CDER: Its Office of Management

Another Reorganization for CDER: Its Office of Management

Posted 15 January 2015 | By Alexander Gaffney, RAC

Another Reorganization for CDER: Its Office of Management

The US Food and Drug Administration's Center for Drug Evaluation and Research (CDER) is already off to a busy start this year, having released new long-sought functions on its website, launched its new Office of Pharmaceutical Quality (OPQ) and hired a permanent director for its Office of Generic Drugs.

The changes, it seems, aren't stopping there. Last week, CDER also announced a reorganization of its Office of Management in the hopes of streamlining its approach to managing the nation's drug regulators.

In an email to FDA staff on 8 January 2015, CDER Director Janet Woodcock said the new management staff will include two additions: a strategic programs and initiatives staff, and an ethics liaison staff.

The overall will also see the creation of two new divisions:

  • The Division of User Fee Management and Budget Formulation (DUFMBF), which will oversee the generics branch, legal and operations branch, and the brands branch.
  • The Division of Budget Execution and Resource Management (DBERM), which will replace the Division of Management and Budget and oversee three branches: budget execution, acquisitions support and financial accountability.

A third division, the Division of Management Services (DMS), which oversees most of CDER's HR functions, will continue to exist with some minor changes. CDER also said it plans to eliminate a total of six branches:

  • Program and Resource Management Branch
  • Management Analysis Branch
  • Program and Resource Management Branch
  • Management Analysis Branch
  • Program Management Services Branch
  • Interface Management Branch

Woodcock said the reorganization will help CDER to "better meet the management services needs of a growing Center with expanding authorities" under the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012.


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.